Krsnaa Diagnostics slips 15% as Rajasthan NHM cancels agreement

The National Health Mission, Rajasthan has cancelled the letter of acceptance (LoA) for providing laboratory services in the state under the free diagnostics initiative on the hub and spoke model.

market, stocks, stock market trading, stock market
SI Reporter Mumbai
2 min read Last Updated : Jul 20 2023 | 1:21 PM IST

Don't want to miss the best from Business Standard?

Shares of Krsnaa Diagnostics declined 15 per cent to Rs 452.45 in Thursday’s intra-day trade, after the National Health Mission Rajasthan cancelled the letter of acceptance (LoA) for providing laboratory services in the state under free diagnostics initiative on the hub and spoke model.

However, the company said that the cancellation of LoA does not in any way impact its existing business operations.

“We remain steadfast in our commitment to expanding our business in both existing and recently executed agreements across various geographies,” the company said.

Also Read

At 12:58 pm; the stock traded 12 per cent lower at Rs 468.20, as compared to 0.26 per cent gain in the S&P BSE Sensex. With Thursday's decline, the market price of the company has corrected 26 per cent from its 52-week high level of Rs 609.15, touched on June 12, 2023.

In May 2023, the company had accepted letter of award issued by National Health Mission, Rajasthan "the authority" for providing "Laboratory Services under Free Diagnostics Initiative on HUB and SPOKE Model under NHM" in the entire state of Rajasthan to the company in consortium with the telecommunications consultants India Ltd (TCIL) (100 per cent Government of India Undertaking) as lead bidder.

"As part of tender requirements, there were requirements of provision of submitting additional performance security. There are disagreements over providing of this additional performance security due to certain technicalities," Krsnaa Diagnostics said.

The company, further, said in collaboration with TCIL, it has taken legal recourse and legal counsels are actively pursuing this matter with utmost dedication and diligence.

Krsnaa Diagnostics is India’s fastest growing differentiated diagnostic services provider both in Radiology and Pathology.


*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Buzzing stocksKrsnaa Diagnosticsstocks to watchMarket trendsBSE NSE

First Published: Jul 20 2023 | 1:21 PM IST

Next Story